Traditionally, the Indian pharmaceutical industry has been characterized by a core competency in generics’ manufacturing and relatively immature capabilities in R&D. This outlook has evolved substantially since the 1990s and Indian companies have been making investments towards expanding drug discovery and development capabilities. The acceptance of patent laws and the rise of contract manufacturing have led to the diversification of revenue streams, enabling Indian pharma companies to experience high market growth.
Report highlights
Presenting the Datamonitor report: “The Indian Pharmaceutical Market to 2011: Competitive dynamics and major players.” This insightful compilation provides a detailed analysis of the leading players and discusses how they are planning to sustain growth over the next five years. For each company, this report analyzes current and future therapeutic focus, sales growth, key pipeline products and future growth prospects. This report will help you to identify the critical success factors that have driven company growth, evaluate diversification opportunities and assess the future potential of each company’s R&D portfolio over the next five years.
<
Key reasons to purchase this report
- Gain insights from the best practices of the top 10 Indian pharma companies, by reviewing detailed profiles of current and future drug portfolios, growth strategies and organizational structure.
- Assess the pipeline strength of the top 10 Indian Pharma companies and identify future opportunities for growth.
- Evaluate how market share of leading companies, such as Ranbaxy, Cipla, Nicholas Piramal, Sun Pharma and Zydus Cadila will change over the next 5 years.
- Benchmark forecast performance of the leading players by using analysis of key products in major indications.
- Identify which therapy areas offer the greatest opportunity by evaluating the therapeutic focus of the competition.
Key questions answered in this report
- What are the challenges faced by pharmaceutical companies in the Indian market?
- How has the re-introduction of patent regime affected Indian pharmaceutical companies?
- What are the market shares for the 10 leading Indian companies 2005?
- Which of the top 10 companies are out performing and under performing in the current market situation and why?
- What are the major strengths, weaknesses, opportunities and threats for the market leaders?
- Which of the 10 companies features the most promising R&D pipeline and how will this impact future growth?
To order or to receive a FREE excerpt of this pharmaceutical marketing special report, ‘The Indian Pharmaceutical Market to 2011: Competitive dynamics and major players’, produced by Datamonitor and distributed by ePharmaceuticals™, a division of HCPro, Inc., call 877/437-4276 or e-mail epharm@hcpro.com. Orders must be paid in full before shipment. All sales are final; no returns or refunds are permitted with this product.
Save money when you purchase multiple copies! Ask your customer service representative about money-saving
discounts and bulk orders. Call toll free 800-650-6787 or e-mail
customerservice@hcpro.com.
